Participants can access the meeting via the Lumi Connect platform. Detailed instructions regarding voting procedures and meeting participation are available through the investor relations portal on the company’s official website.
Cardiol Therapeutics continues to focus its research on CardiolRx, a small-molecule drug candidate targeting inflammation and fibrosis. The company is currently managing the MAVERIC program, which includes an ongoing Phase III trial for recurrent pericarditis, as well as development efforts for CRD-38, a novel subcutaneous formulation intended to treat inflammatory heart disease.
Comments (0)
No comments yet. Be the first!